{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:07:42Z","timestamp":1789243662275,"version":"build-2803163510"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2023\/006869"],"award-info":[{"award-number":["CRG\/2023\/006869"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4-4\/18\/ mh\/2022-NCD-11"],"award-info":[{"award-number":["5\/4-4\/18\/ mh\/2022-NCD-11"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116751","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:07:35Z","timestamp":1778490455000},"page":"116751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FcRn-targeted therapeutics: Neonatal fc receptor at the Interface of balancing immune modulation and persevering protective humoral immunity"],"prefix":"10.1016","volume":"182","author":[{"given":"Devlina","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116751_bb0005","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ajh.27487","article-title":"Current state and potential applications of neonatal fc receptor (FcRn) inhibitors in hematologic conditions","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2026.116751_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","article-title":"FcRn inhibitor therapies in neurologic diseases","volume":"38","author":"Alfaidi","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.intimp.2026.116751_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103719","article-title":"FcRn inhibitors: transformative advances and significant impacts on IgG-mediated autoimmune diseases","volume":"24","author":"Zhu","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2026.116751_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14728214.2025.2458061","article-title":"FcRn inhibitors in the context of myasthenia gravis","volume":"30","author":"Menon","year":"2025","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.intimp.2026.116751_bb0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116751_bb0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0040","doi-asserted-by":"crossref","first-page":"159s","DOI":"10.1083\/jcb.99.1.159s","article-title":"Receptor-mediated transport of IgG","volume":"99","author":"Rodewald","year":"1984","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116751_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic fc engineering \u2013 modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.118.5.845","article-title":"Factors controlling serum \u03b3-globulin concentration","volume":"118","author":"Fahey","year":"1963","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0055","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0060","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1021\/bi000749m","article-title":"Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related fc receptor(,)","volume":"39","author":"West","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2026.116751_bb0065","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1006\/jmbi.1993.1220","article-title":"Crystallization and stoichiometry of binding of a complex between a rat intestinal fc receptor and fc","volume":"230","author":"Huber","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2026.116751_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/372379a0","article-title":"Crystal structure of the complex of rat neonatal fc receptor with fc","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116751_bb0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/eji.1830240308","article-title":"Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis","volume":"24","author":"Kim","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0080","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/eji.1830241025","article-title":"Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal fc receptor","volume":"24","author":"Kim","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0085","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","article-title":"Crystal structure at 2.8 \u00c5 of an FcRn\/heterodimeric fc complex","volume":"7","author":"Martin","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2026.116751_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0969-2126(98)00008-2","article-title":"Structural basis of pH-dependent antibody binding by the neonatal fc receptor","volume":"6","author":"Vaughn","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.intimp.2026.116751_bb0095","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116751_bb0100","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal fc receptor: Biological consequences","volume":"169","author":"Acqua","year":"2002","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0105","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116751_bb0115","series-title":"Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0","first-page":"399","author":"Saxena","year":"2018"},{"key":"10.1016\/j.intimp.2026.116751_bb0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and Allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0125","first-page":"18","article-title":"Serum immunoglobulins and risk of infection: how Low can you go?, Semin","volume":"39","author":"Furst","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2026.116751_bb0130","doi-asserted-by":"crossref","unstructured":"J. Sigurjonsson, D. Grubb, A. Grubb, A. Christensson, C.M. \u00d6berg, P. Ederoth, S. Koul, M. G\u00f6tberg, T. Yndigegn, T. T\u00f6dt, B. Viterius, H. Bjursten, A study of size-selective renal elimination using a novel human model, Scand. J. Clin. Lab. Invest. 84 (2024) 115\u2013120. Doi: https:\/\/doi.org\/10.1080\/00365513.2024.2338742.","DOI":"10.1080\/00365513.2024.2338742"},{"key":"10.1016\/j.intimp.2026.116751_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1521432","article-title":"Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients","volume":"16","author":"Man\u00e9-Damas","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with Bortezomib depletes plasma cells and specific autoantibody production in primary Thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.immuni.2016.07.003","article-title":"Long-lived plasma cells have a sweet tooth","volume":"45","author":"Corcoran","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116751_bb0150","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0155","article-title":"Fc\u03b3RIIB functions as an IgG transporter in the mammary gland","volume":"123","author":"Li","year":"2026","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","article-title":"Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life","volume":"196","author":"Spiekermann","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0170","first-page":"160","article-title":"Efficacy of the placental barrier for immunoglobulins: correlations between maternal, paternal and fetal immunoglobulin levels","volume":"103","author":"Avrech","year":"1994","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0180","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.4049\/jimmunol.166.5.3266","article-title":"MHC class I-related neonatal fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells","volume":"166","author":"Zhu","year":"2001","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01166-22","article-title":"Human FcRn is a two-in-one attachment-Uncoating receptor for echovirus 18","volume":"13","author":"Chen","year":"2022","journal-title":"MBio"},{"key":"10.1016\/j.intimp.2026.116751_bb0190","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1038\/s41467-024-51142-x","article-title":"The neonatal fc receptor (FcRn) is a pan-arterivirus receptor","volume":"15","author":"Shaw","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2020.12.024","article-title":"Demonstration of fibrinogen-FcRn binding at acidic pH by means of fluorescence correlation spectroscopy","volume":"536","author":"Vesco","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12979-024-00455-y","article-title":"The immunology of B-1 cells: from development to aging","volume":"21","author":"Mattos","year":"2024","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.intimp.2026.116751_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1061651","article-title":"Human B-1 cells are important contributors to the naturally-occurring IgM pool against the tumor-associated ganglioside Neu5GcGM3","volume":"13","author":"Rodriguez-Zhurbenko","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade1413","article-title":"T-independent responses to polysaccharides in humans mobilize marginal zone B cells prediversified against gut bacterial antigens","volume":"8","author":"Weller","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri3383","article-title":"Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes","volume":"13","author":"Cerutti","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4049\/jimmunol.1400844","article-title":"Natural antibodies bridge innate and adaptive immunity","volume":"194","author":"Panda","year":"2014","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0225","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116751_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699563","article-title":"DAMPs and innate immune training","volume":"12","author":"Jentho","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0235","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116751_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/smim.1994.1039","article-title":"CD40 ligation in B cell activation, isotype switching and memory development","volume":"6","author":"Gray","year":"1994","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0245","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.4049\/jimmunol.1401849","article-title":"IgH chain class switch recombination: mechanism and regulation","volume":"193","author":"Stavnezer","year":"2014","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/TP.0b013e3181e7e54f","article-title":"The role of the Thymus in tolerance","volume":"90","author":"Griesemer","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2026.116751_bb0255","doi-asserted-by":"crossref","first-page":"1154575","DOI":"10.3389\/fimmu.2023.1154575","article-title":"Regulatory T cells in peripheral tissue tolerance and diseases","volume":"14","author":"Cheru","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0260","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4 + T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102962","article-title":"Infectious diseases, autoantibodies, and autoimmunity","volume":"137","author":"Johnson","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2026.116751_bb0270","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1038\/s41467-024-53658-8","article-title":"Molecular mimicry as a mechanism of viral immune evasion and autoimmunity","volume":"15","author":"Maguire","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2026.116751_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"HLA-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0285","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/ar89","article-title":"Association of MHC and rheumatoid arthritis. HLA-DR4 and rheumatoid arthritis: studies in mice and men","volume":"2","author":"Fugger","year":"2000","journal-title":"Arthritis Res."},{"key":"10.1016\/j.intimp.2026.116751_bb0290","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri.2016.9","article-title":"AIRE expands: new roles in immune tolerance and beyond","volume":"16","author":"Anderson","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0305","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116751_bb0310","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0315","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0320","doi-asserted-by":"crossref","first-page":"J223","DOI":"10.1016\/j.jaut.2011.11.018","article-title":"Neonatal autoimmune diseases: a critical review","volume":"38","author":"Chang","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2026.116751_bb0325","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11832-015-0690-8","article-title":"Maternal myasthenia gravis: a cause for arthrogryposis multiplex congenita","volume":"9","author":"Midelfart Hoff","year":"2015","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.intimp.2026.116751_bb0330","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2026.116751_bb0335","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in \u03b22-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0340","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0345","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal fc receptor expression in macrophages is indispensable for IgG homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116751_bb0350","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.186.5.777","article-title":"\u03b22-microglobulin\u2013deficient mice are resistant to bullous pemphigoid","volume":"186","author":"Liu","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0355","first-page":"1328","article-title":"The MHC class I\u2013like fc receptor promotes humorally mediated autoimmune disease","volume":"113","author":"Akilesh","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2026.116751_bb0360","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jps.20297","article-title":"Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and Alloimmune conditions","volume":"94","author":"Getman","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0365","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"The Journal of Immunology"},{"issue":"498","key":"10.1016\/j.intimp.2026.116751_bb0370","first-page":"e1","article-title":"M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model","volume":"220","author":"Roy","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.intimp.2026.116751_bb0375","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/bph.14986","article-title":"Treatment with anti-neonatal fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice","volume":"177","author":"Kasprick","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116751_bb0380","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","article-title":"Neonatal fc receptor blockade by fc engineering ameliorates arthritis in a murine model","volume":"187","author":"Patel","year":"2011","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0385","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/mabs.25439","article-title":"Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis","volume":"5","author":"Challa","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116751_bb0390","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/31430955-703b-484a-96eb-e180f917d683","article-title":"The neonatal fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells","volume":"9","author":"Gupta","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2026.116751_bb0400","doi-asserted-by":"crossref","first-page":"eaav3208","DOI":"10.1126\/sciadv.aav3208","article-title":"Maternal immunity and antibodies to dengue virus promote infection and Zika virus\u2013induced microcephaly in fetuses","volume":"5","author":"Rathore","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.116751_bb0405","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chom.2018.10.008","article-title":"Cross-reactive dengue virus antibodies augment Zika virus infection of human placental macrophages","volume":"24","author":"Zimmerman","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.intimp.2026.116751_bb0410","article-title":"Inhibition of maternal-to-fetal transfer of IgG antibodies by FcRn blockade in a mouse model of arthrogryposis multiplex Congenita., neurology(R)","volume":"8","author":"Coutinho","year":"2021","journal-title":"Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.intimp.2026.116751_bb0415","first-page":"37","article-title":"Neuropathogenesis of Zika virus infection\u00a0: potential roles of antibody-mediated pathology","volume":"41","author":"Tsunoda","year":"2016","journal-title":"Acta Med. Kinki Univ."},{"key":"10.1016\/j.intimp.2026.116751_bb0420","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cell.2019.04.035","article-title":"Human neonatal fc receptor is the cellular Uncoating receptor for enterovirus B","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116751_bb0425","doi-asserted-by":"crossref","unstructured":"X. Chen, J. Li, J. Guo, W. Xu, S. Sun, Z. Xie, An outbreak of echovirus 18 encephalitis\/meningitis in children in Hebei Province, China, 2015, Emerg. Microbes Infect. 6 (2017) 1\u20133. Doi: https:\/\/doi.org\/10.1038\/emi.2017.39.","DOI":"10.1038\/emi.2017.39"},{"key":"10.1016\/j.intimp.2026.116751_bb0430","doi-asserted-by":"crossref","first-page":"515","DOI":"10.15585\/mmwr.mm6718a2","article-title":"Enterovirus and Parechovirus surveillance \u2014 United States, 2014\u20132016","volume":"67","author":"Abedi","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.intimp.2026.116751_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104516","article-title":"Non-polio enterovirus infections in children with central nervous system disorders in Shanghai, 2016-2018: serotypes and clinical characteristics","volume":"129","author":"Li","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.intimp.2026.116751_bb0440","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/gtc.13160","article-title":"Neonatal fc receptor is a functional receptor for classical human astrovirus","volume":"29","author":"Haga","year":"2024","journal-title":"Genes Cells"},{"key":"10.1016\/j.intimp.2026.116751_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01218-24","article-title":"The neonatal fc receptor (FcRn) is required for porcine reproductive and respiratory syndrome virus uncoating","volume":"99","author":"Yang","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2026.116751_bb0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116751_bb0455","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal fc receptor (FcRn) confers protective immunity to vaginal infection","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.116751_bb0460","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00038-18","article-title":"Cellular and humoral immunity protect against vaginal Zika virus infection in mice","volume":"92","author":"Scott","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2026.116751_bb0465","doi-asserted-by":"crossref","first-page":"18406","DOI":"10.1073\/pnas.1115348108","article-title":"Intracellular neutralization of viral infection in polarized epithelial cells by neonatal fc receptor (FcRn)-mediated IgG transport","volume":"108","author":"Bai","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0470","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.2100297","article-title":"FcRn-targeted mucosal vaccination against influenza virus infection","volume":"207","author":"Ochsner","year":"2021","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116751_bb0475","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.1038\/s41467-023-42796-0","article-title":"An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0480","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2016.11.025","article-title":"Protective efficacy of fc targeting conserved influenza virus M2e antigen expressed by lactobacillus plantarum","volume":"138","author":"Yang","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2026.116751_bb0485","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1038\/s41564-024-01855-y","article-title":"The neonatal fc receptor is a cellular receptor for human astrovirus","volume":"9","author":"Ingle","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.intimp.2026.116751_bb0490","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2026.116751_bb0495","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116751_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0505","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2026.116751_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.intimp.2026.116751_bb0515","unstructured":"J.A. Allen, J. Lin, I. Basta, T. Dysgaard, C. Eggers, J.T. Guptill, K.G. Gwathmey, C. Hewamadduma, E. Hofman, Y.M. Hussain, S. Kuwabara, G. Le Masson, F. Leypoldt, T. Chang, M. Lipowska, M. Lowe, G. Lauria, L. Querol, M.-A. Simu, N. Suresh, A. Tse, P. Ulrichts, B. Van Hoorick, R. Yamasaki, R.A. Lewis, P.A. van Doorn, ADHERE study group, safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial, Lancet Neurol. 23 (2024) 1013\u20131024. Doi: Safety,tolerability,andefficacyofsubcutaneousefgartigimodinpatientswithchronicinflammatorydemyelinatingpolyradiculoneuropathy(ADHERE):amul."},{"key":"10.1016\/j.intimp.2026.116751_bb0520","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116751_bb0525","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40261-024-01380-0","article-title":"Pharmacokinetics and pharmacodynamics of Nipocalimab, a neonatal fc receptor blocker, in healthy Japanese volunteers","volume":"44","author":"Matsushima","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.intimp.2026.116751_bb0530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Vivacity-MG3 study group, safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2026.116751_bb0535","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Vivacity-MG Phase 2 Study Group, Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2026.116751_bb0540","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0545","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/cts.13019","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2026.116751_bb0550","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2026.116751_bb0555","doi-asserted-by":"crossref","unstructured":"C. ISRCTN Study contact, Safety, tolerability, pharmacokinetics, and pharmacodynamics of single\/multiple doses of IMVT-1402 in healthy participants, London, UK, 2023. Doi: https:\/\/doi.org\/10.1186\/ISRCTN11659633.","DOI":"10.1186\/ISRCTN11659633"},{"key":"10.1016\/j.intimp.2026.116751_bb0560","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241307687","article-title":"First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report","volume":"17","author":"Kwiedor","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2026.116751_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863095","article-title":"FcRn antagonism leads to a decrease of Desmoglein-specific B cells: secondary analysis of a phase 2 study of Efgartigimod in pemphigus vulgaris and pemphigus Foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0575","article-title":"Unknown Immunoregulatory effects of FcRn inhibition by Efgartigimod in myasthenia gravis: a new mechanism of action beyond IgG reduction., neurology(R)","volume":"12","author":"Tarasco","year":"2025","journal-title":"Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.intimp.2026.116751_bb0580","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.116751_bb0585","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin Levels, infectious risk, and mortality with rituximab and Hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.intimp.2026.116751_bb0590","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1128\/IAI.72.10.5807-5813.2004","article-title":"Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization","volume":"72","author":"McCool","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2026.116751_bb0595","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftx022","article-title":"Innate immune recognition and inflammation in Neisseria meningitidis infection","volume":"75","author":"Johswich","year":"2017","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.intimp.2026.116751_bb0600","doi-asserted-by":"crossref","first-page":"1409480","DOI":"10.3389\/fimmu.2024.1409480","article-title":"Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review","volume":"15","author":"Ge","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0605","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1172\/JCI27821","article-title":"Neonatal fc receptor for IgG regulates mucosal immune responses to luminal bacteria","volume":"116","author":"Yoshida","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2026.116751_bb0610","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mi.2011.53","article-title":"Neonatal fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice","volume":"5","author":"Ben Suleiman","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0615","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2470542","article-title":"Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models","volume":"21","author":"Warang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116751_bb0620","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2491269","article-title":"A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants","volume":"21","author":"Cossu","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116751_bb0625","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2586335","article-title":"Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: a disproportionality analysis based on the FAERS database","volume":"21","author":"Liu","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116751_bb0630","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/IM9.0000000000000183","article-title":"Varicella-zoster virus reactivation during Efgartigimod therapy for generalized myasthenia gravis: a report of two cases","volume":"7","author":"Li","year":"2025","journal-title":"Infectious Microbes and Diseases"},{"key":"10.1016\/j.intimp.2026.116751_bb0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","article-title":"Efflux of monoclonal antibodies from rat brain by neonatal fc receptor, FcRn","volume":"1534","author":"Cooper","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2026.116751_bb0640","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-020-60438-z","article-title":"Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn","volume":"10","author":"Ruano-Salguero","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116751_bb0645","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2026.116751_bb0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0655","first-page":"611","article-title":"Heterogeneity of basal membranes in human tissues detected by monoclonal antibodies to laminin and entactin., Biull. Eksp","volume":"105","author":"Peklo","year":"1988","journal-title":"Biol. Med."},{"key":"10.1016\/j.intimp.2026.116751_bb0660","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0665","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0404.1977.tb01445.x","article-title":"Genetic aspects in myasthenia gravis","volume":"56","author":"Pirskanen","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.intimp.2026.116751_bb0670","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Res. Hum. Genet."},{"key":"10.1016\/j.intimp.2026.116751_bb0675","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.smim.2011.01.015","article-title":"Genetic predisposition to autoimmunity \u2013 what have we learned?","volume":"23","author":"Rai","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100122","article-title":"Ways in which the neonatal fc-receptor is involved in autoimmunity","volume":"4","author":"Lamamy","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.intimp.2026.116751_bb0685","doi-asserted-by":"crossref","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2026.116751_bb0690","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ajt.15913","article-title":"The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection","volume":"20","author":"Jordan","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2026.116751_bb0695","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cei\/uxae011","article-title":"Albumin influences leucocyte FcRn expression in the early days of kidney transplantation","volume":"216","author":"Boulard","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2026.116751_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0705","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12977-017-0380-3","article-title":"Systems serology: profiling vaccine induced humoral immunity against HIV","volume":"14","author":"Chung","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.intimp.2026.116751_bb0710","doi-asserted-by":"crossref","unstructured":"U. Laserson, F. Vigneault, D. Gadala-Maria, G. Yaari, M. Uduman, J.A. Vander Heiden, W. Kelton, S. Taek Jung, Y. Liu, J. Laserson, R. Chari, J.-H. Lee, I. Bachelet, B. Hickey, E. Lieberman-Aiden, B. Hanczaruk, B.B. Simen, M. Egholm, D. Koller, G. Georgiou, S.H. Kleinstein, G.M. Church, High-resolution antibody dynamics of vaccine-induced immune responses, Proceedings of the National Academy of Sciences 111 (2014) 4928\u20134933. Doi: https:\/\/doi.org\/10.1073\/pnas.1323862111.","DOI":"10.1073\/pnas.1323862111"},{"key":"10.1016\/j.intimp.2026.116751_bb0715","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-023-00613-1","article-title":"Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design","volume":"8","author":"Loos","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.intimp.2026.116751_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116679","article-title":"Structural hijacking of FcRn by human astrovirus spikes reveals conserved epitopes for broad-spectrum antivirals","volume":"44","author":"Agrawal","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116751_bb0725","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1038\/s41467-025-65203-2","article-title":"Structure of the human astrovirus capsid spike in complex with the neonatal fc receptor","volume":"16","author":"Lentz","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116751_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1013316","article-title":"Functional characterization of DPP4 and FcRn as receptor and coreceptor for classical human astroviruses in Caco-2 cells","volume":"21","author":"Aguilera-Flores","year":"2025","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2026.116751_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255796","article-title":"Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand","volume":"16","author":"Tandhavanant","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116751_bb0740","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70436","article-title":"Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis","volume":"15","author":"Li","year":"2025","journal-title":"Clin. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:56:00Z","timestamp":1789242960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926005977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":148,"alternative-id":["S1567576926005977"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116751","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FcRn-targeted therapeutics: Neonatal fc receptor at the Interface of balancing immune modulation and persevering protective humoral immunity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116751"}}